Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adamis Pharmaceuticals Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ADMP
Nasdaq
2834
http://www.adamispharmaceuticals.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adamis Pharmaceuticals Corp
Adamis Appoints Vickie Reed to Board of Directors
- May 26th, 2022 8:05 pm
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
- May 18th, 2022 9:00 pm
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
- May 16th, 2022 8:35 pm
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
- May 9th, 2022 9:56 pm
5 Winning Stocks to Land on the Overlooked Rising P/E Trick
- May 9th, 2022 11:17 am
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
- Mar 31st, 2022 8:49 pm
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
- Mar 31st, 2022 8:14 pm
Acutus Medical, Inc. (AFIB) Reports Q4 Loss, Tops Revenue Estimates
- Mar 30th, 2022 9:15 pm
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates
- Mar 30th, 2022 12:15 am
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates
- Mar 28th, 2022 9:25 pm
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
- Mar 24th, 2022 11:30 am
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
- Mar 22nd, 2022 11:30 am
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
- Mar 21st, 2022 8:05 pm
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
- Mar 14th, 2022 12:17 pm
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
- Mar 4th, 2022 12:30 pm
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
- Feb 28th, 2022 12:30 pm
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 18th, 2022 9:05 pm
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
- Feb 7th, 2022 2:17 pm
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
- Jan 10th, 2022 12:30 pm
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?
- Dec 20th, 2021 3:00 pm
Scroll